5.15
-0.07(-1.36%)
Currency In USD
| Previous Close | 5.15 |
| Open | 5.11 |
| Day High | 5.23 |
| Day Low | 5.01 |
| 52-Week High | 8.14 |
| 52-Week Low | 3.81 |
| Volume | 13,288 |
| Average Volume | 126,998 |
| Market Cap | 52.79M |
| PE | -5.6 |
| EPS | -0.92 |
| Moving Average 50 Days | 5.22 |
| Moving Average 200 Days | 5.25 |
| Change | -0.07 |
If you invested $1000 in Serina Therapeutics Inc (SER) since IPO date, it would be worth $53.21 as of October 16, 2025 at a share price of $5.15. Whereas If you bought $1000 worth of Serina Therapeutics Inc (SER) shares 5 years ago, it would be worth $75.89 as of October 16, 2025 at a share price of $5.15.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
GlobeNewswire Inc.
Oct 08, 2025 3:00 PM GMT
HUNTSVILLE, AL., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the launch o
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease
GlobeNewswire Inc.
Oct 06, 2025 8:15 PM GMT
$5 million tranche received under up to $20 million financing agreementIND submitted to FDA and HREC approval obtained in Australia; global trial initiation in Q4 2025 HUNTSVILLE, AL, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Se
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease
GlobeNewswire Inc.
Sep 09, 2025 7:20 PM GMT
Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathwayEvaluating complementary funding including strategic equity and non-dilutive alternati